TABLE 1.

Baseline characteristics of the 75 immunocompromised patients infected with the BA.1 or BA.2 Omicron subvariants of SARS‐CoV‐2 and treated with CCP.

Patient baseline characteristics (n = 75)
Age, years, median [IQR]	65 [59–73]
Female/male, n	28/47
Days from symptoms onset to CCP, days, median [IQR]	17 [10–24,5]
Initial CT level, median [IQR]	22.9 [17.5–26]
Anti‐CD20 mAb pre‐exposure (n = 73, unknown = 2), n (%)
Yes	51 (70)
No	22 (30)
Pre exposure to monoclonal antibodies (n = 75), n (%)
Yes	7 (9)
No	68 (91)
Two‐dose vaccination (n = 75), n (%)
Yes	68 (91)
No	7 (9)
Initial anti‐S antibodies (n = 70, unknown = 5), n (%)
>264 BAU/mL	8 (11)
<264 BAU/mL	62 (89)
Underlying diseases (n = 71, excluded patients with two simultaneous underlying immunodeficiency n = 4), n (%)
Hematological malignancy	50 (71)
Solid organ transplant recipient	11 (15)
Autoimmune disease	10 (14)
Positive RNAemia (n = 18, unknown = 57), n (%)
Yes	13 (72)
No	5 (28)
WHO scale (n = 72, unknown = 3), n (%)
Scale 5	49 (68)
Scale 6	23 (32)

Note: WHO clinical progression scale for the COVID‐19 severity: Scale 5: hospitalized, oxygen by mask or nasal prongs, WHO 6: hospitalized, oxygen by noninvasive ventilation or high flow [9].

Abbreviations: BAU, binding antibody unit; CCP, COVD‐19 convalescent plasma; mAb, monoclonal antibody.